Scarica l'app Stockscreener
7.88
9.75%
0.70
Pre-mercato:
8.14
0.26
+3.30%
Precedente Chiudi:
$7.18
Aprire:
$7.25
Volume 24 ore:
638.19K
Relative Volume:
0.95
Capitalizzazione di mercato:
$345.11M
Reddito:
-
Utile/perdita netta:
$-110.66M
Rapporto P/E:
-2.545
EPS:
-3.0963
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
+2.60%
1M Prestazione:
+23.90%
6M Prestazione:
+176.49%
1 anno Prestazione:
+59.19%
Intervallo 1D:
$7.22
$8.19
Intervallo di 1 settimana:
$6.45
$8.19
Portata 52W:
$1.78
$8.4471
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
7.88 | 314.46M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-05-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
| 2024-03-04 | Iniziato | JP Morgan | Overweight |
| 2024-03-04 | Iniziato | Leerink Partners | Outperform |
| 2024-03-04 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics Inc Stock Analysis and ForecastShort Interest Overview & High Yield Trading Alerts - earlytimes.in
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
6 Companies Hanging On in Cell Therapy - BioSpace
Aug Gainers: What margin trends mean for Kyverna Therapeutics Inc. stock2025 Key Lessons & Real-Time Chart Pattern Alerts - BỘ NỘI VỤ
FY2025 Earnings Estimate for KYTX Issued By HC Wainwright - MarketBeat
Trend Recap: Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases - TipRanks
Why Kyverna Therapeutics Inc. stock remains resilient2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
How sentiment analysis helps forecast Kyverna Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsWeekly Profit Summary & Verified Entry Point Signals - newser.com
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX) - Seeking Alpha
KYTX: KYV-101 delivers transformative results in autoimmune diseases, targeting first-to-market leadership - TradingView
KYTX: KYV101 demonstrates transformative efficacy and safety in autoimmune diseases, targeting first-to-market leadership - TradingView
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
What analysts say about Kyverna Therapeutics Inc stockVWAP Trading Strategies & Calculate Profit Targets With AI Accuracy - earlytimes.in
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Myasthenia Gravis Market is expected to grow at a CAGR of 10.4% by 2034, estimates DelveInsight - Barchart.com
What analyst consensus says on Kyverna Therapeutics Inc. stockJuly 2025 Update & Stepwise Trade Signal Guides - Fundação Cultural do Pará
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential - Seeking Alpha
Combining price and volume data for Kyverna Therapeutics Inc.Trade Analysis Summary & Detailed Earnings Play Alerts - newser.com
Kyverna Therapeutics (NASDAQ:KYTX) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):